Sana Biotechnology, Inc.

NasdaqGS:SANA Rapport sur les actions

Capitalisation boursière : US$1.0b

Sana Biotechnology Gestion

Gestion contrôle des critères 4/4

Le PDG Sana Biotechnology est Steve Harr, nommé en Sep2018, a un mandat de 7.92 ans. La rémunération annuelle totale est $ 2.90M, composée du salaire de 24% et des bonus 76%, y compris les actions et options de la société. détient directement 2.99% des actions de la société, d'une valeur de $ 30.56M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2 ans et 7.8 ans.

Informations clés

Steve Harr

Directeur général

US$2.9m

Rémunération totale

Pourcentage du salaire du PDG23.98%
Durée du mandat du directeur général7.9yrs
Propriété du PDG3.0%
Durée moyenne d'occupation des postes de direction2yrs
Durée moyenne du mandat des membres du conseil d'administration7.8yrs

Mises à jour récentes de la gestion

Recent updates

Seeking Alpha • Jul 22

Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation

Summary Sana Biotechnology is rated Sell due to excessive risk and overvaluation relative to its early-stage pipeline. Both lead assets, SC291 and SC451, are years from market and face low historical success rates, with SC291 only in Phase 1. The entire pipeline depends on the unproven Hypoimmune (HIP) platform; failure in early trials could invalidate the company. With $128.9M in cash and high burn, heavy dilution is likely for SANA, making the current $3.14 share price unjustified versus a $0.53 risk-adjusted fair value. Read the full article on Seeking Alpha
Seeking Alpha • Mar 25

Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421

Summary SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which also received FDA Fast Track for r/r SLE, extrarenal lupus, and lupus nephritis. However, UP421 might be the most promising. It restored insulin production in a type 1 diabetes patient. SANA also has ongoing Phase 1 trials for SC291 and SC262, with topline data expected in 2025. However, SANA does have high cash burn and dilution risks, which is why I just rate it a speculative “Buy”. Read the full article on Seeking Alpha
Seeking Alpha • Jan 08

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success

Summary Sana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered cells were accepted by the patient's immune system without immunosuppression, a potential game-changing breakthrough that has stumped scientists for >75 years. Although the data is from a single patient, the potential market opportunity for a functional cure for Type 1 diabetes is immense. I rate SANA stock as a “Buy,” but advise caution as the stock may correct downward before long-term growth, given the early stage of clinical progress. Read the full article on Seeking Alpha
Seeking Alpha • Dec 04

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

Summary Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025. The FDA's Fast Track Designation for SC291 could expedite its review, addressing unmet medical needs in autoimmune disorders. Sana is also developing SC262 for relapsed/refractory B-cell malignancies, with data expected by the end of 2024 or in 2025. The global Lupus drugs market is expected to reach $4.2 billion by 2031. Read the full article on Seeking Alpha
Seeking Alpha • Nov 19

Sana Biotechnology: The Story Becomes Murkier

Summary Sana Biotechnology, Inc.'s stock has dropped from around $9 to under $2.50 since mid-March, when we last took a look at this engineered-cell therapy concern. Earlier this month, the company suspended two of its developmental programs to improve its pipeline focus and lower its cash burn rate to extend its “cash runway.”. The analyst community is also quite mixed around Sana Biotechnology's current prospects, but some additional trial data should be posted in the near future. An updated analysis around Sana Biotechnology follows in the paragraphs below. Read the full article on Seeking Alpha
Article d’analyse • Nov 01

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jul 14

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Summary Sana Biotechnology is a biotech company focused on developing engineered allogeneic cells for diseases with unmet clinical needs. Sana's most advanced product candidates leverage CRISPR technology to modify cells, with positive pre-clinical trial results and first in-human trials starting in late 2023. The company's pipeline includes oncology, autoimmune disease, and regenerative medicine product candidates, with a focus on UP421 and SC291 for T1DM and B-cell malignancies, respectively. Read the full article on Seeking Alpha
Article d’analyse • Jul 12

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 17

Sana Biotechnology: Now In Overbought Territory

Summary Sana Biotechnology's shares have risen some 60% since a secondary offering in February, driven by positive early clinical and research results. The company is focused on developing engineered cells to treat diseases, using a hypoimmune technology platform to create cells that evade immune detection. Sana has three clinical programs in Phase 1 trials, with promising results seen in the treatment of B-cell cancer and type I diabetes. A full analysis around Sana Biotechnology follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jan 11

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Summary Sana Biotechnology's novel T1D treatment, not requiring immunosuppression, shows encouraging results in a non-human primate study. Sana displays improved Q3 financials with a current ratio of 4.03, but faces high cash burn and potential funding needs. Investment Stance: Shift from "Sell" to "Hold" based on Sana's financial management and R&D progress, with a watchful eye for further clinical and financial developments. Read the full article on Seeking Alpha
Article d’analyse • Dec 30

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Article d’analyse • Sep 14

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse • May 26

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse • Dec 19

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Article d’analyse • Sep 03

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Jun 27

Sana Biotechnology A Buy For Potential Cancer Therapies

Preclinical stage company has cash, expertise, and platform for success. Recent preclinical data showed potential of its technology. Clinical trials could begin in 2023, following INDs in 2022.
Article d’analyse • May 16

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Feb 12

Sana Biotechnology: Exciting Preclinical Science

Sana was formed by founders of Juno. It has very exciting science and encouraging preclinical data. However, risks abound.
Article d’analyse • Oct 13

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Sana Biotechnology...

Analyse de la rémunération des PDG

Comment la rémunération de Steve Harr a-t-elle évolué par rapport aux bénéfices de Sana Biotechnology?
DateRémunération totaleSalaireBénéfices de l'entreprise
Mar 31 2026n/an/a

-US$242m

Dec 31 2025US$3mUS$696k

-US$244m

Sep 30 2025n/an/a

-US$234m

Jun 30 2025n/an/a

-US$252m

Mar 31 2025n/an/a

-US$209m

Dec 31 2024US$9mUS$681k

-US$267m

Sep 30 2024n/an/a

-US$306m

Jun 30 2024n/an/a

-US$245m

Mar 31 2024n/an/a

-US$309m

Dec 31 2023US$3mUS$659k

-US$283m

Sep 30 2023n/an/a

-US$276m

Jun 30 2023n/an/a

-US$362m

Mar 31 2023n/an/a

-US$320m

Dec 31 2022US$4mUS$645k

-US$269m

Sep 30 2022n/an/a

-US$300m

Jun 30 2022n/an/a

-US$298m

Mar 31 2022n/an/a

-US$207m

Dec 31 2021US$1mUS$611k

-US$356m

Sep 30 2021n/an/a

-US$358m

Jun 30 2021n/an/a

-US$327m

Mar 31 2021n/an/a

-US$433m

Dec 31 2020US$7mUS$535k

-US$285m

Rémunération vs marché: La rémunération totale de Steve ($USD 2.90M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 3.59M ).

Rémunération et revenus: La rémunération de Steve a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Steve Harr (56 yo)

7.9yrs
Titularisation
US$2,903,010
Compensation

Dr. Steven D. Harr, also known as Steve, M.D., is President and Chief Executive Officer at Sana Biotechnology, Inc. since September 2018 and also serves as its Director since October 2018. He served as the...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Steven Harr
President7.9yrsUS$2.90m2.99%
$ 30.6m
Brian Piper
Executive VP & CFOless than a yearpas de donnéespas de données
Susan Wyrick
Treasurer1.8yrspas de données0.065%
$ 669.0k
Snehal Patel
Senior VP & Chief Technical Officer2.6yrspas de donnéespas de données
Dhavalkumar Patel
Executive VP & Chief Scientific Officer2yrspas de données0.033%
$ 339.3k
Aaron Grossman
Executive VPless than a yearpas de donnéespas de données
Debra Wisdom
VP & Head of Peopleno datapas de donnéespas de données
Gary Meininger
Chief Medical Officer3.3yrspas de donnéespas de données
Yuko Soneoka
Head of Intellectual Property2yrspas de donnéespas de données
John Gerecitano
Head of Oncology Research & Development2yrspas de donnéespas de données
2.0yrs
Durée moyenne de l'emploi
54yo
Âge moyen

Gestion expérimentée: L'équipe de direction de SANA est considérée comme expérimentée (ancienneté moyenne 2 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Steven Harr
President7.8yrsUS$2.90m2.99%
$ 30.6m
Robert Taylor Nelsen
Independent Director7.8yrsUS$162.79k0.0046%
$ 47.2k
Yuhmin Yang
Independent Director7.8yrsUS$167.79k0.050%
$ 509.0k
Michelle Seitz
Independent Director5.8yrsUS$182.79k0%
$ 0
Richard Mulligan
Vice Chairman7.8yrsUS$162.79k0.90%
$ 9.2m
Hans Edgar Bishop
Independent Chairman of the Board7.8yrsUS$220.51k1.95%
$ 20.0m
Joshua Bilenker
Independent Director5.7yrsUS$169.52k0.0067%
$ 68.2k
Alise Reicin
Independent Director5.7yrsUS$170.29k0%
$ 0
Robert Rosiello
Independent Director1.2yrsUS$230.70k0%
$ 0
7.8yrs
Durée moyenne de l'emploi
64yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de SANA sont considérés comme expérimentés (ancienneté moyenne 7.8 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/08/07 22:32
Cours de l'action en fin de journée2026/08/07 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Sana Biotechnology, Inc. est couverte par 12 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Alec StranahanBofA Global Research
Samantha Lynn SemenkowCitigroup Inc
Reni BenjaminCitizens JMP Securities, LLC